149 related articles for article (PubMed ID: 36971780)
21. Differential expression of IGFBPs in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence.
Somri L; Sarfstein R; Lapkina-Gendler L; Nagaraj K; Laron Z; Bach LA; Werner H
Growth Horm IGF Res; 2018 Apr; 39():6-12. PubMed ID: 29208357
[TBL] [Abstract][Full Text] [Related]
22. Transgenic Wuzhishan minipigs designed to express a dominant-negative porcine growth hormone receptor display small stature and a perturbed insulin/IGF-1 pathway.
Li F; Li Y; Liu H; Zhang X; Liu C; Tian K; Bolund L; Dou H; Yang W; Yang H; Staunstrup NH; Du Y
Transgenic Res; 2015 Dec; 24(6):1029-42. PubMed ID: 26510874
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA 132-3p Is Upregulated in Laron Syndrome Patients and Controls Longevity Gene Expression.
Yaron-Saminsky D; Nagaraj K; Sarfstein R; Laron Z; Pasmanik-Chor M; Werner H
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769292
[TBL] [Abstract][Full Text] [Related]
24. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome.
Laron Z; Kauli R; Lapkina L; Werner H
Mutat Res Rev Mutat Res; 2017; 772():123-133. PubMed ID: 28528685
[TBL] [Abstract][Full Text] [Related]
25. Growth hormone induces insulin resistance in Laron dwarf cells via lactogenic receptors.
Geffner ME; Bersch N; Golde DW
J Clin Endocrinol Metab; 1993 Apr; 76(4):1039-47. PubMed ID: 8473379
[TBL] [Abstract][Full Text] [Related]
26. Novel growth hormone receptor mutation in a Chinese patient with Laron syndrome.
Hui HN; Metherell LA; Ng KL; Savage MO; Camacho-Hübner C; Clark AJ
J Pediatr Endocrinol Metab; 2005 Feb; 18(2):209-13. PubMed ID: 15751611
[TBL] [Abstract][Full Text] [Related]
27. The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency.
Laron Z
Hormones (Athens); 2008; 7(1):24-7. PubMed ID: 18359741
[TBL] [Abstract][Full Text] [Related]
28. Identification of UDP-Glucuronosyltransferase 2B15 (UGT2B15) as a Target for IGF1 and Insulin Action.
Sarfstein R; Nagaraj K; Parikh S; Levy C; Laron Z; Benayahu D; Werner H
Cells; 2022 May; 11(10):. PubMed ID: 35626664
[TBL] [Abstract][Full Text] [Related]
29. LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME.
Laron Z
Endocr Pract; 2015 Dec; 21(12):1395-402. PubMed ID: 26401581
[TBL] [Abstract][Full Text] [Related]
30. Brain Structure and Function Associated with Younger Adults in Growth Hormone Receptor-Deficient Humans.
Nashiro K; Guevara-Aguirre J; Braskie MN; Hafzalla GW; Velasco R; Balasubramanian P; Wei M; Thompson PM; Mather M; Nelson MD; Guevara A; Teran E; Longo VD
J Neurosci; 2017 Feb; 37(7):1696-1707. PubMed ID: 28073935
[TBL] [Abstract][Full Text] [Related]
31. Identification of nephronectin as a new target for IGF1 action.
Sarfstein R; Lapkina-Gendler L; Nagaraj K; Laron Z; Werner H
Eur J Cancer; 2020 Dec; 141():115-127. PubMed ID: 33130549
[TBL] [Abstract][Full Text] [Related]
32. Fanconi Anemia and Laron Syndrome.
Castilla-Cortazar I; de Ita JR; Aguirre GA; Castorena-Torres F; Ortiz-Urbina J; García-Magariño M; de la Garza RG; Diaz Olachea C; Elizondo Leal MI
Am J Med Sci; 2017 May; 353(5):425-432. PubMed ID: 28502327
[TBL] [Abstract][Full Text] [Related]
33. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.
Laron Z; Kauli R
Growth Horm IGF Res; 2016 Jun; 28():53-6. PubMed ID: 26307357
[TBL] [Abstract][Full Text] [Related]
34. Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action.
Nagaraj K; Lapkina-Gendler L; Sarfstein R; Gurwitz D; Pasmanik-Chor M; Laron Z; Yakar S; Werner H
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):1045-1050. PubMed ID: 29339473
[TBL] [Abstract][Full Text] [Related]
35. Assessing insulin sensitivity and resistance in syndromes of severe short stature.
Guevara-Aguirre J; Teran E; Lescano D; Guevara C; Guevara A; Saavedra J; Procel P; Wasserfall C; Gavilanes AWD
Growth Horm IGF Res; 2020; 53-54():101339. PubMed ID: 32763832
[TBL] [Abstract][Full Text] [Related]
36. Genome-Wide Profiling of Laron Syndrome Patients Identifies Novel Cancer Protection Pathways.
Werner H; Lapkina-Gendler L; Achlaug L; Nagaraj K; Somri L; Yaron-Saminsky D; Pasmanik-Chor M; Sarfstein R; Laron Z; Yakar S
Cells; 2019 Jun; 8(6):. PubMed ID: 31208077
[TBL] [Abstract][Full Text] [Related]
37. Energy balance, physical activity, and cancer risk.
Fair AM; Montgomery K
Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
[TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report.
Laron Z; Ginsberg S; Webb M
Growth Horm IGF Res; 2008 Oct; 18(5):434-438. PubMed ID: 18462969
[TBL] [Abstract][Full Text] [Related]
39. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment.
Laron Z; Avitzur Y; Klinger B
Metabolism; 1995 Oct; 44(10 Suppl 4):113-8. PubMed ID: 7476303
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 cotreatment versus insulin-like growth factor-I alone in two brothers with growth hormone insensitivity syndrome: effects on insulin sensitivity, body composition and linear growth.
Ekström K; Carlsson-Skwirut C; Ritzén EM; Bang P
Horm Res Paediatr; 2011; 76(5):355-66. PubMed ID: 21968387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
